Pfizer PFE Short-term debt and current portion of long-term debt
Short-term debt and current portion of long-term debt at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:DebtCurrent.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's short-term debt and current portion of long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pfizer's short-term debt and current portion of long-term debt?
- Pfizer (PFE) reported short-term debt and current portion of long-term debt of $3.89B in Q1 2026.
- How has Pfizer's short-term debt and current portion of long-term debt changed year-over-year?
- Pfizer's short-term debt and current portion of long-term debt decreased by 13.0% year-over-year, from $4.47B to $3.89B.
- What is the long-term trend for Pfizer's short-term debt and current portion of long-term debt?
- Over 5 years (2020 to 2025), Pfizer's short-term debt and current portion of long-term debt has grown at a 3.1% compound annual growth rate (CAGR), from $2.7B to $3.15B.